Analyst Ratings For Apellis Pharmaceuticals (NASDAQ:APLS) (NASDAQ:APLS)
Today, JPMorgan Chase & Co. reiterated its Overweight rating on Apellis Pharmaceuticals (NASDAQ:APLS) (NASDAQ:APLS) with a price target of $35.00.
Some recent analyst ratings include
- 3/23/2018-JPMorgan Chase & Co. Reiterated Rating of Overweight .
- 2/8/2018-B. Riley initiated coverage with a Buy rating.
- 12/4/2017-Evercore ISI initiated coverage with a Outperform rating.
- 12/4/2017-Citigroup initiated coverage with a Buy rating.
- On 11/13/2017 Global Strategic Fund I Venbio, Major Shareholder, bought 127,515 with an average share price of $14.00 per share and the total transaction amounting to $1,785,210.00.
Recent Trading Activity for Apellis Pharmaceuticals (NASDAQ:APLS) (NASDAQ:APLS)
Shares of Apellis Pharmaceuticals (NASDAQ:APLS) closed the previous trading session at 24.01 up +0.27 1.14% with 150 shares trading hands.
